Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. *Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.* 

## Effect of Caffeine-Containing Beverages on Physicochemical and Release Properties of Halofantrine

Chinedum Peace BABALOLA<sup>1</sup> and Chinedum Peace BABALOLA<sup>2</sup>

<sup>1</sup> University of Ibadan

Received: 15 December 2013 Accepted: 1 January 2014 Published: 15 January 2014

#### 7 Abstract

3

5

Halofantrine (Hf) is a poorly water-soluble drug for treating malaria in endemic areas like 8 tropical Africa, where caffeine-containing products are habitually consumed. Previous reports 9 showed that caffeine increased the aqueous solubility of Hf at room temperature over 3 days. 10 The aim of this study was to determine the effect of caffeine and caffeine containing beverages 11 on dissolution and solubility of Hf and to investigate any possible interactions. The aqueous 12 solubility and dissolution of Hf alone and in the presence of caffeine was investigated at pH 13 1.3, 5.9 and 7.4 using standard methods. The solubility of Hf in the presence of aqueous 14 extracts of cocoa, coffee, black tea and green tea at pH 5.9 was also investigated. In 1 hour, 15 caffeine markedly increased the aqueous solubility of Hf at pH 1.3, 5.9 and 7.4. Caffeine and 16 caffeine-containing beverages markedly increased the aqueous solubility of Hf by between 100-17 to more than 1600- fold, with a 1672-fold increase by caffeine (from 76.6  $\pm$ 7.8 ng/mL to128.2 18  $\pm$  4.5 mg/mL) at pH 5.9. The dissolution of Hf tablets at pH 1.3, 5.9 and 7.4 showed the 19 respective amounts released as  $3.57 \pm 0.09$ ,  $0.95 \pm 0.19$  and  $0.260 \pm 0.043$  mg, but 20 introduction of caffeine increased these values to  $9.51 \pm 0.23$ ,  $3.70 \pm 0.12$  and  $0.52 \pm 0.10$  mg 21 respectively, representing 3-fold, 4-fold and 2-fold respectively. These results prove 22 physico-chemical interaction between caffeine and halofantrine. The consequence of this 23 finding is unknown but may affect malaria chemotherapy when Hf is administered 24 concurrently with caffeine-containing products. 25

26

27 Index terms— caffeine, halofantrine, physicochemical interaction.

#### 28 1 Introduction

alofantrine (Hf) is a phenanthrene methanol antimalarial currently marketed as halofantrine hydrochloride under
the trade name Halfan®. Hf, a highly lipophilic drug [1] has been shown to be highly active against multidrug
resistant isolates of Plasmodium falciparum in preclinical studies [2,3,4]. The drug has proven efficacy against
multi-drug resistant malaria including infection with chloroquine and/or pyrimethamine resistant strains of P.
falciparum [5].

Hf is highly lipophilic [1,6] with an erratic oral absorption pattern leading to high inter individual variations that have been shown to be associated with food intake ??7 -10]. Lim and Go (2000) reported that caffeine, a non-toxic complexing agent that possesses stimulant effect on the CNS, enhanced the aqueous solubility of Hf [11] at room temperature for over 3 days by a 1:1 ratio complex formation. In a different study by Kolade et al. (2008) kolanut, a habitually consumed nut rich in caffeine, also increased the solubility of Hf in vitro but decreased the plasma concentrations of the drug in humans [12].

Aside of kolanut that contains caffeine, other caffeine-containing beverages such as, coffee, cocoa, black tea and green tea are also habitually consumed in the tropics where malaria is prevalent. There is thus a need for

# 9 H) DISSOLUTION PROFILE OF HF TABLETS ALONE AND IN THE PRESENCE OF CAFFEINE

42 investigations of Hf interactions with caffeine and caffeine-containing beverages especially at various pH values

43 that are important in GIT for orally administered medicines. Therefore the aim of this study was to determine the

effect of caffeine and caffeine containing beverages on the solubility and dissolution profile of Hf at physiologically
 important pH values of 1.3, 5.9 and 7.4 as well as to investigate any possible interactions.

## 6 **2** II.

46

## 47 **3** Materials and Methods

## <sup>48</sup> 4 a) Chemicals and Reagents

Halofantrine hydrochloride (Hf) was received as a gift from Smithkline Beecham (Welwyn Garden City, United
Kingdom). Caffeine, coffee (Coffee arabica), cacao (Theobroma cacao), black tea Ccamellia sinensis), and green
tea Ccamellia sinensis) were obtained commercially. Potassium dihydrogen phosphate (analar) and sodium
chloride (analar) were obtained from VWR International (Darmstrdt, Germany). Instruments used were basket

type Easy-lift dissolution test station, Mettler Delta 340, pH meter, Uniscope SM b) Preparation of 0.05M KH

- 54 2 PO 4 (ionic strength = 0.08)
- Standard solutions of 0.05M potassium dihydrogen phosphate were prepared and adjusted to pH 1.3, 5.9 and 7.4 respectively

## <sup>57</sup> 5 c) Calibration line for Hf

The HPLC method for determination of Hf in plasma previously described [12] was adapted for this study. Mobile phase samples (1mL) were spiked with standard solutions of Hf to give predetermined concentrations of 200, 500, 1000, 2000, 4000, and 8000ng/mL. 40mL of 1mg/mL chlorprothixen was measured into a 100mL volumetric

flask and diluted to volume with methanol to produce 400µg/mL chlorprothixen solution. To each 1mL mobile phase sample was added 20µL of 400µg/mL internal standard solution (chlorprothixen) to produce 8000ng/mL.

<sup>63</sup> Aliquots of 20 μL were then injected into the HPLC. The peak area ratio (Hf/IS) obtained for each sample was

64 plotted against the corresponding concentration to obtain the calibration line.

## 65 6 d) Determination of solubility of Hf in KH 2 PO 4 buffers

(pH 1.3, 5.9, 7.4) To 5mg of Hf weighed into a test tube, 5mL of phosphate buffer (pH 5.9) was added to it.
The mixture was then shaken in a water bath at 37 o C for 1h after which it was centrifuged at 4000 rpm for 15
minutes to get a clear supernatant. The procedure was repeated with buffers of pH 1.3 and 7.4. After centrifuging,
20µL of the supernatant were injected into the HPLC and the concentrations of Hf were extrapolated from the

70 calibration line.

## 71 7 e) Interactions of Hf with caffeine

72 0.6063g of caffeine was weighed into a volumetric flask and made up to 25mL with phosphate buffer (pH 5.9).

5mL each of this preparation was placed in three different test tubes. An excess of Hf was weighed into each test

tube and the test tubes were placed on a water bath adjusted to 37 o C and shaken for 1h. The solutions were

rs centrifuged at 4000rpm for 15 minutes and the supernatants collected and analyzed for Hf. The procedure was

 $_{\rm 76}$   $\,$  repeated using phosphate buffers pH 1.3 and 7.4.

## 77 8 f) Preparation of extracts of caffeine-containing beverages

The seeds of Coffee arabica were powdered using a mortar and pestle. 2.5g of the powdered coffee seeds were 78 dissolved in 25mL of KH 2 PO 4 buffer (0.05M, ionic strength 0.08, pH 5.9) and mixed in a vortex mixer for 79 20 minutes at room temperature. The mixture was then centrifuged at  $4000~\mathrm{rpm}$  for 15 minutes to give a clear 80 supernatant. The same procedure was followed using cocoa powder, black tea leaves and green tea leaves to get 81 the extracts of cocoa, black tea and green tea respectively. g) Interactions of Hf with coffee, cocoa, black tea 82 and green tea 5mg each of Hf was weighed into different test tubes. 5mL of each of the extracts of coffee, cocoa, 83 black tea and green tea equivalent to 2.5g/25mL (100mg/mL) prepared above was then added to the test tube 84 containing the Hf. The mixture was shaken in a water bath at 37 o C for 1h after which it was centrifuged at 4000 85 rpm for 15 minutes to get a clear supernatant. 20µl of the supernatant was injected into the HPLC. Triplicates 86 87 of the above samples were prepared and the concentrations of Hf extrapolated from the calibration line.

# <sup>88</sup> 9 h) Dissolution profile of Hf tablets alone and in the presence <sup>89</sup> of caffeine

A dissolution medium consisting of phosphate buffer : methanol (75:25, v/v) was prepared using buffers at three
different pH values (1.3, 5.9 and 7.4) representing gastric, duodenal and plasma pH values.

Six dissolution vessels containing 500 mL each of buffer (pH 5.9) : methanol (75:25, v/v) was set up. Three

- $_{93}$  of the vessels contained a single tablet of halofantrine hydrochloride (250 mg) alone while the other three vessels
- $_{94}$  contained both a tablet of Hf and 1.95 mg/mL of caffeine. The dissolution stations were maintained at 100 rpm,

and 37 o C for 1h. Samples were taken for analysis at different time intervals of 5, 10, up to 60 minutes. The
procedure was repeated using buffers pH 1.3 and 7.4 respectively. All the determinations were performed in
triplicate and the amount of Hf dissolved was thereafter determined spectrophotometrically.

#### <sup>98</sup> 10 i) Determination of amount of dissolved halofantrine

from tablets UV analysis of the samples was carried out at a wavelength of 310nm. Corresponding concentrations
 of the absorbance readings were obtained using a calibration curve equation constructed from six concentrations
 (2.5 -25µg/mL) of Hf.

#### 102 **11 III.**

#### 103 12 Results

The calibration line of Hf in mobile phase was linear over a concentration range of 100ng/mL to 8000ng/mL with 104 an r 2 of over 0.999. The aqueous solubility of Hf determined at 37 o C for 1 h at pH of 1.3, 5.9 and 7.4 was 105 found to be  $323 \pm 41$ ,  $77 \pm 8$  and  $27 \pm 11$  ng/mL, respectively indicating highest solubility at pH 1.3. Caffeine 106 increased the solubility of Hf at pH 1. 11ng/mL to  $6646 \pm 712 ng/mL$ . Coffee, cocoa, black tea and green tea 107 extracts at a concentration of 2.5g/25mL also increased the solubility of Hf by over a 100-fold in pH 5.9 as shown 108 in Table ??. Coffee and cocoa extracts increased the solubility from  $77 \pm 8$  ng/mL to  $11525 \pm 593$  and 17270109  $\pm$  1680 ng/mL respectively while black For the dissolution rate studies, the amount of Hf dissolved at pH 1.3, 110 5.9 and 7.4 were  $3574.48 \pm 92.53$ ,  $947.93 \pm 194.12$ , and  $259.9 \pm 43.15$  µg respectively, but with the addition of 111 112 caffeine to the dissolution medium, the amount dissolved increased to  $9506.93 \pm 226.6$ ,  $3703.13 \pm 117.98$ , and 113  $522.42 \pm 104.54$  µg of Hf at the same pH values indicating 3-, 4 and 2-folds increment respectively. A plot of 114 amount of Hf dissolved at 60 mins against the physiologic pH revealed the degree of impact caffeine had on the dissolution of Hf. 115

116 IV.

#### 117 **13 Discussion**

The ionic strength of 0.08 was used for the solubility studies of Hf studies because it is at this strength that 118 optimum results was obtained in previous studies [11]. The effect of caffeine on the solubility of Hf investigated 119 at three pH values of 1.3, 5.9 and 7.4 represents gastric, duodenal and physiological pH respectively. pH 5.9 is a 120 good approximation of duodenal pH with or without food and since Hf is administered orally for the treatment of 121 malaria, its solubility profile at this pH will be useful. pH 5.9 was chosen as the pH medium for the interaction of 122 the caffeine-containing beverages with Hf since it gave the optimum results observed with caffeine. The extracts of 123 these beverages increased the solubility of Hf at this pH in the following order: Green tea>Cocoa>Coffee>Black 124 tea. The caffeine contents of these beverages from literature vary and in some cases, the % content overlaps. 125 For example, the % content are; coffee (1-2%), cocoa (0.6-0.36%), green tea and black tea (1-5%) [13,14]. Cocoa 126 which is reported to have the lowest caffeine content was expected to cause minimum solubility on interaction 127 with Hf if the interaction is solely based on caffeine content. However it was placed 2 nd in this study. Cocoa 128 129 also contains cocoa butter which is fatty and since Hf is lipophilic and affected by fatty foods [1,8], it is likely that the cocoa butter may be contributing to the increase in solubility of Hf. 130

Preliminary investigations were carried out to find out the effect of some of the other constituents present in the extracts such as theophylline and trigonelline but these were found to have no effect on the solubility of Hf. The dissolution profile of a drug is an important parameter in evaluating its bioavailability since dissolution precedes absorption. Earlier studies of the aqueous solubility of halofantrine, a poorly soluble and weakly basic drug conducted by Lim and Mei [11] shows that the solubility is greatest at the low pH range of 2.5-3.5 and shows a steep hundred fold decline as the pH is increased to 8.0. This was attributed to a change in the state of protonation of halofantrine.

However, the aqueous solubility of halofantrine in phosphate buffer pH 5.9 and 7.4 was found to be increased
by the addition of caffeine and nicotinamide; of which pH 5.9 showed the greatest solubility [11].

Fig. ?? shows the calibration curve generated for the absorbance measurement of Hf at 310nm. The curve
was linear over a range of 2.5-25µg/mL with a regression coefficient and coefficient of determination of 0.996 &
0.993 respectively.

The solubility of halofantrine was then determined both in the absence and presence of caffeine. The dissolution profiles (Figs. ?? & 3) reveal an increase in the amount of Hf dissolved in the presence of caffeine for all the physiologic pH values.

The amount of Hf dissolved increased by 3-, 4and 2-folds in the presence of caffeine at pH 1.3, 5.9 and 7.4 respectively. This solubility enhancement has been attributed to complex formation between caffeine and Hf in accordance with the ? -donor ? -receptor mechanism proposed by Fawzi et al [18] and Abdul et al [19].

The amount of the drug dissolved at 60 mins at the various pH values also clearly shows that caffeine had a great impact on the dissolution of halofantrine. Fig. ?? shows r 2 of 0.972 with caffeine and 0.897 without caffeine. The decrease in the amount of halofantrine that dissolved at 60 mins with pH increase is as a result of the weakly basic nature of the drug. Since many drugs exist as either weakly basic or weakly acidic compounds, their ionization in water which also influences their solubility and absorption is influenced by pH. In the presence of an acidic pH, a weakly basic drug dissolves better as it is able to form a soluble salt. However the dissolution diminishes as the pH is increased and the weakly basic drug tend to precipitate ??20].

The analysis of variance (2-way ANOVA) on the amount of halofantrine dissolved at the 60 mins shows that a highly significant (p<0.001) interaction exists between the effect of caffeine and the pH effect on the dissolution of this drug.

159 V.

### 160 14 Conclusion

Caffeine enhances the solubility of halofantrine in a remarkable way and beverages that contain varying amounts of it also have similar effect as shown in the effects of coffee, cacao, black and green tea. It is obvious that these extracts that contain caffeine increased the in vitro solubility of Hf markedly. Although in vitro analyses of Hf in the presence of caffeine and caffeine-containing beverages show increase in the amount of Hf, an in vivo study recently carried out showed a decrease in the concentration of Hf when coadministered with kolanut -a caffeine containing nut (Kolade et al 2008). Whether in vivo studies involving coffee, cacao, black tea and green tea will give replicate results as kolanut still remains to be investigated.

Although in vitro results do not correspond with in vivo effect of caffeine on Hf, it still is evident that caffeine, either in pure form or as a constituent of food, does impact on the profile of Hf when co-administered and therefore the ingestion of the two together must be closely monitored in order to determine therapeutic importance of these findings.

#### 172 15 Volume XIV Issue I Version I



Figure 1:

173

1

<sup>&</sup>lt;sup>1</sup>© 2014 Global Journals Inc. (US)




Figure 2: B




Figure 3: Figure 3 : Figure 4 :

- [Ann Trop Med Parasitol ()], Ann Trop Med Parasitol 1984. 78 (1) p. . 174
- [Bryson et al. ()] 'A review of its antimalarial activity, pharmacokinetic properties and therapeutic potential'. H 175 M Bryson, K L Goa, Halofantrine. Drugs 1992. (2) p. . 176
- [Aideloje et al. ()] 'Altered Altered pharmacokinetics of halofantrine by an antacid, magnesium carbonate'. S O 177 Aideloje, C O Onyeji, N C Ugwu. Eur J Pharm Biopharm 1998. 46 (3) p. . 178
- [Kolade et al. ()] 'Analysis of the antimalarial drug halofantrine and its major metabolite N-desbutylhalofantrine 179 in human plasma by high performance liquid chromatography'. Y T Kolade, C P Babalola, G K Scriba. J 180
- Pharm Biomed Anal 2006. (1) p. . 181
- [Schmidt et al. ()] 'Antimalarial activities of various 9-phenanthrenemethanols with special attention to WR-182
- 122,455 and WR-171,669'. L H Schmidt , R Crosby , J Rasco , D Vaughan . Antimicrob Agents Chemother 183 1978. 14 (3) p. . 184
- [Colwell et al. ()] 'Antimalarial arylaminopropanols'. W T Colwell, V Brown, P Christie, J Lange, C Reece, 185 K Yamamoto , D W Henry . J Med Chem 1972. 1972 (7) p. . 186
- [Lim and Go ()] 'Caffeine and nicotinamide enhances the aqueous solubility of the antimalarial agent halo-187 fantrine'. L Lim, M Go. Eur J Pharm Sci 2000. 10 (1) p. . 188
- [Childs et al.] Comparison of in vitro and in vivo, G E Childs, C Lambros, J D Notsch, C L Pamplin, Davidson 189 DeJr, A Ager. 190
- [Tanaka et al. ()] 'Contents of caffeine, theobromine and theophylline in favorite foods'. T Tanaka, A Okayama 191 , S Seguchi , M Ohhashi , S Tahara , M Tamaki . Nara Prefect. Inst. Public Health 2000. 34 p. . 192
- [Babalola et al. ()] 'Determination of physicochemical properties of halofantrine'. C P Babalola, A O Adegoke, 193 M A Ogunjimi, M O Osimosu. Afr. J. Med. Med. Sci 2003. 32 (4) p. . 194
- 195 [Kolade et al. ()] 'Effect of kolanut on the pharmacokinetics of the antimalarial drug halofantrine'. Y T Kolade , C P Babalola, A A Olaniyi, G K Scriba. Eur J Clin Pharmacol 2008. 64 (1) p. . 196
- [Bassi et al. ()] 'Effects of tetracycline on the pharmacokinetics of halofantrine in healthy volunteers'. P U Bassi 197 , C O Onyeji , O E Ukponmwan . Br J Clin Pharmacol 2004. 58 (1) p. . 198
- [Watkins et al. ()] 'Efficacy of multiple-dose halofantrine in treatment of chloroquine-resistant falciparum malaria 199 in children in Kenya'. W M Watkins , J A Oloo , J D Lury , M Mosoba , D Kariuki , M Mjomba , D K Koech 200 , H M Gilles . Lancet 1988. 30 (8605) p. . 201
- [Cosgriff et al. ()] 'Evaluation of the antimalarial activity of the phenanthrenemethanol halofantrine (WR 202 171,669)'. T M Cosgriff, E F Boudreau, C L Pamplin, E B Doberstyn, R E Desjardins, C J Canfield. Am 203
- J Trop Med Hyg 1982. (6) p. . 204

210

- [Ter Kuile et al. ()] 'Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria'. F 205 O Ter Kuile, G Dolan, F Nosten, M D Edstein, C Luxemburger, L Phaipun, T Chongsuphajaisiddhi, H 206
- K Webster, N J White . Lancet 1993. 341 (8852) p. . 207
- [Boudreau et al. ()] 'Malaria: treatment efficacy of halofantrine (WR 171,669) in initial field trials in Thailand'. 208 E F Boudreau , L W Pang , K E Dixon , H K Webster , K Pavanand , L Tosingha , P Somutsakorn , C J 209 Canfield . Bull World Health Organ 1988. 66 (2) p. .
- [Milton et al. ()] 'Pharmacokinetics of halofantrine in man: effects of food and dose size'. K A Milton, G Edwards 211 , S A Ward , M L Orme , A M Breckenridge . Br J Clin Pharmacol 1989. 28 (1) p. . 212
- [Monlun et al. ()] 'Prolonged QT interval with halofantrine'. E Monlun, O Pillet, J F Cochard, Favarel 213 Garrigues, J C Le Bras, M. Lancet 1993. (8859) p. . 214
- [Fawzi et al. ()] 'Rationalization of drug complexation in aqueous solution by use of Hückel frontier molecular 215 orbitals'. M B Fawzi, E Davison, M S Tute. J Pharm Sci 1980. (1) p. . 216
- [Rasool et al. ()] 'Solubility enhancement of some water-insoluble drugs in the presence of nicotinamide and 217 related compounds'. A A Rasool, A A Hussain, L W Dittert . J Pharm Sci 1991. 80 (4) p. . 218